

Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

Sp2/0-Ag14

RRID:CVCL_2199

Type: Cell Line

Proper Citation

KCLB Cat# 21581, RRID:CVCL_2199

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2199

Proper Citation: KCLB Cat# 21581, RRID:CVCL_2199

Description: Cell line Sp2/0-Ag14 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Mouse multiple myeloma

Defining Citation: [PMID:714156](#), [PMID:1373425](#), [PMID:6769123](#), [PMID:31220119](#)

Comments: Group: Hybridoma fusion partner cell line.

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: Sp2/0-Ag14

Synonyms: SP2/0-Ag14, SP2/0-AG14, SP2/0-ag14, Sp2/O-Ag14, SP2/O-Ag14, Sp2/0-Ag-14, SP2-0-Ag14, SP2/0 Ag-14, SP-2/0-AG14, Sp 2/0-Ag 14, SP2/0AG14, Sp2/0, SP2/0, Sp2/O, SP2/O, SP-2, SP2, GM03569, GM3569, GM03569B, GM3569B, GM03569D

Cross References: BTO:BTO_0002291, CLO:CLO_0009112, CLO:CLO_0009113, CLO:CLO_0009114, CLO:CLO_0009115, CLO:CLO_0017241, CLO:CLO_0050178, CLDB:cl4382, CLDB:cl4383, CLDB:cl4384, CLDB:cl4385, CLDB:cl4386, AddexBio:C0033005/4967, ATCC:CRL-1581, ATCC:CRL-8287, BCRC:60034, BCRJ:0227, BioSample:SAMN11397630, CCRID:1101MOU-PUMC000054, CCRID:1102MOU-NIFDC00011, CCRID:3101MOUTCM18, CCRID:3101MOUTCM42, CCRID:4201MOU-CCTCC00019, CCRID:5301MOU-KCB92021YJ, CCRID:6101MOU-CERC000118, CCTCC:GDC0019, CLS:400481, Coriell:GM03569, DSMZ:ACC-146,

DSMZCellDive:ACC-146, ECACC:85072401, IBRC:C10106, JCRB:JCRB9084, KCB:KCB 92021YJ, KCLB:21581, Lonza:329, NCBI_Iran:C129, RCB:RCB0209, TKG:TKG 0248, Wikidata:Q54955446

ID: CVCL_2199

Vendor: KCLB

Catalog Number: 21581

Hierarchy: cvcl_3411

Record Creation Time: 20220427T221554+0000

Record Last Update: 20260920T005812+0000

Ratings and Alerts

No rating or validation information has been found for Sp2/0-Ag14.

No alerts have been found for Sp2/0-Ag14.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 553 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Bi B, et al. (2026) MCT8 Modulates Metabolite Uptake and T-cell Exhaustion to Promote Immunosuppression and Tumor Progression in Hepatocellular Carcinoma. Molecular cancer therapeutics, 25(5), 771.

Diaz-Jimenez A, et al. (2026) EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis. Cancer discovery, 16(1), 46.

Aalilouch K, et al. (2026) Development and characterization of monoclonal antibodies against inhibin β subunit as a potential cancer biomarker. Analytical biochemistry, 712, 116066.

Hu Z, et al. (2026) Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. Immunity, 59(7), 1928.

Schild T, et al. (2025) Metabolic engineering to facilitate anti-tumor immunity. Cancer cell, 43(3), 552.

- Zoeller JJ, et al. (2025) Derivation of AZD5335, a Novel FR α -Targeted TOP1 α -Loaded ADC, for the Treatment of FR α -Expressing Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(24), 5261.
- Kurihara M, et al. (2025) Analysis of site-dependent mucins in rat intestinal mucosa using anti-glycan monoclonal antibodies. *Glycoconjugate journal*, 42(3-4), 187.
- Yang C, et al. (2025) A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity. *Cell reports. Medicine*, 6(10), 102409.
- Mitchell JS, et al. (2024) CD4 $^{+}$ T cells reactive to a hybrid peptide from insulin-chromogranin A adopt a distinct effector fate and are pathogenic in autoimmune diabetes. *Immunity*, 57(10), 2399.
- Tian J, et al. (2024) ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms. *Cancer immunology research*, 12(5), 592.
- Mineva ND, et al. (2024) A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer. *Pharmaceutics*, 16(4).
- Peng Y, et al. (2024) Non-IL-2-blocking anti-CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti-CTLA-4 therapy. *International journal of cancer*, 154(7), 1285.
- Liao B, et al. (2024) Development of a therapeutic monoclonal antibody against circulating adipocyte fatty acid binding protein to treat ischaemic stroke. *British journal of pharmacology*, 181(8), 1238.
- Royet A, et al. (2024) Nonstructural protein 4 of human norovirus self-assembles into various membrane-bridging multimers. *The Journal of biological chemistry*, 300(9), 107724.
- Okano F, et al. (2023) Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. *Cancer research communications*, 3(4), 640.
- Goo D, et al. (2023) Collagen adhesin protein and necrotic enteritis B-like toxin as biomarkers for early diagnosis of necrotic enteritis in commercial broiler chickens. *Poultry science*, 102(6), 102647.
- Zhang F, et al. (2023) Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies. *Nature microbiology*, 8(6), 1051.
- Zhang Y, et al. (2023) Immunization with a novel mRNA vaccine, TGGT1_216200 mRNA-LNP, prolongs survival time in BALB/c mice against acute toxoplasmosis. *Frontiers in immunology*, 14, 1161507.
- Hagoss YT, et al. (2023) Novel Epitopes Mapping of African Swine Fever Virus CP312R Protein Using Monoclonal Antibodies. *Viruses*, 15(2).
- Clubb JHA, et al. (2023) Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting. *Frontiers in immunology*, 14, 1060540.